毒素注射可以改善患有帕金森病的患者的口水缩症
Domenico Antonio Restivo1,2, Mario Stampanoni Bassi3,4, Angelo Alito5
1Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Toxins
|February 26, 2026
概括
毒素A型注射到唾液腺有效减少唾液流和改善吞在帕金森病 (PD) 患者. 这种治疗改善了临床评分和吞功能的神经生理学测量.
科学领域:
- 神经学 神经学
- 胃肠病学 胃肠病学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
背景情况:
- 帕金森病 (PD) 经常导致残疾的唾液流和失消.
- 唾液清理受损和口腔运动控制减少有助于PD患者的这些症状.
研究的目的:
- 评估毒素A型 (BoNT/A) 对改善PD患者流口水的吞功能的疗效.
- 评估BoNT/A唾液腺注射对临床和神经生理学吞参数的影响.
主要方法:
- 20名患有严重唾液流和失消的PD患者接受了双边超声导向的BoNT/A注射,注射到状腺和下部腺.
- 临床评估包括透-吸收量表和缺食症严重程度评分量表.
- 神经生理学评估涉及吞相关肌肉和喉运动的电肌图和机械肌图.
主要成果:
- 治疗BoNT/A治疗导致流口水的持续减少.
- 在注射后的1,8周和12周,临床食症得分有显著的改善.
- 神经生理学吞参数在所有随访时间点都显示出显著的改善.
结论:
- 总而言之,对唾液腺注射的IncobotulinumtoxinA在减少唾液流和改善PD患者的吞方面是有效的.
- 通过更好的唾液管理,治疗可以通过改善口腔运动协调来增强吞.
相关概念视频
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Skeletal Muscle Relaxants: Therapeutic Uses
1.1K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.1K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.3K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.3K
Depolarizing Blockers: Pharmocokinetics
666
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
666
Myasthenia Gravis: Overview and Treatment
3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K


